OTCPK:OCPN.Y

Stock Analysis Report

Executive Summary

Olympus Corporation manufactures and sells precision machineries and instruments worldwide.

Snowflake

Fundamentals

Flawless balance sheet with questionable track record.


Similar Companies

Share Price & News

How has Olympus's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-5.3%

OTCPK:OCPN.Y

1.9%

US Medical Equipment

2.1%

US Market


1 Year Return

11.7%

OTCPK:OCPN.Y

13.6%

US Medical Equipment

-0.04%

US Market

OCPN.Y underperformed the Medical Equipment industry which returned 13.6% over the past year.

OCPN.Y outperformed the Market in United States of America which returned -0% over the past year.


Share holder returns

OCPN.YIndustryMarket
7 Day-5.3%1.9%2.1%
30 Day5.8%-0.2%-3.2%
90 Day-4.9%10.2%2.8%
1 Year11.7%11.7%14.5%13.6%2.2%-0.04%
3 Year39.2%39.2%70.2%65.0%41.5%32.3%
5 Year27.7%27.7%133.6%106.8%55.0%37.8%

Price Volatility Vs. Market

How volatile is Olympus's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Olympus undervalued based on future cash flows and its price relative to the stock market?

49.99x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Olympus's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Olympus's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Olympus is overvalued based on earnings compared to the US Medical Equipment industry average.

Olympus is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Olympus is poor value based on expected growth next year.


Price Based on Value of Assets

Olympus is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Olympus expected to perform in the next 1 to 3 years based on estimates from 14 analysts?

12.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Olympus's revenue is expected to grow by 4.5% yearly, however this is not considered high growth (20% yearly).

Olympus's earnings are expected to grow by 12.7% yearly, however this is not considered high growth (20% yearly).

Olympus's revenue growth is positive but not above the United States of America market average.

Olympus's earnings growth is positive but not above the United States of America market average.

Olympus's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Olympus is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Olympus performed over the past 5 years?

9.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Olympus's year on year earnings growth rate has been positive over the past 5 years.

Olympus's 1-year earnings growth exceeds its 5-year average (10.4% vs 9.3%)

Olympus's earnings growth has not exceeded the US Medical Equipment industry average in the past year (10.4% vs 28.9%).


Return on Equity

Olympus has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Olympus used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Olympus's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Olympus's financial position?


Financial Position Analysis

Olympus is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Olympus's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Olympus's level of debt (40%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (119.2% vs 40% today).

Debt is well covered by operating cash flow (40.8%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 111.8x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 2.6x debt.


Next Steps

Dividend

What is Olympus's current dividend yield, its reliability and sustainability?

0.99%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Olympus's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.49%).

Olympus's dividend is below the markets top 25% of dividend payers in United States of America (3.82%).

Olympus is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.

Olympus is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.


Current Payout to Shareholders

No need to calculate the sustainability of Olympus's dividends as it is not paying a notable one for United States of America.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Olympus's salary, the management and board of directors tenure and is there insider trading?

0.3yrs

Average management tenure


CEO

Yasuo Takeuchi (62yo)

0.3yrs

Tenure

0

Mr. Yasuo Takeuchi has been Chief Executive Officer and President of Olympus Corporation since April 1, 2019 and has been its Representative Executive Officer since 2019. He served as Chief Financial Offic ...


Management Age and Tenure

0.3yrs

Average Tenure

61.5yo

Average Age

The average tenure for the Olympus management team is less than 2 years, this suggests a new team.


Board Age and Tenure

3.2yrs

Average Tenure

66.5yo

Average Age

The tenure for the Olympus board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Yasuo Takeuchi (62yo)

    President

    • Tenure: 0.3yrs
  • Akihiro Taguchi (61yo)

    COO & Senior Corporate Managing Executive Officer

    • Tenure: 0.3yrs
  • Haruo Ogawa (62yo)

    CTO & Senior Executive Managing Officer

    • Tenure: 3.3yrs
  • Stefan Kaufmann (51yo)

    Chief Administrative Officer

    • Tenure: 0.2yrs
  • Yasushi Sakai

    CFO & Corporate Managing Officer

    • Tenure: 0.3yrs
  • Masamichi Handa

    Corporate Officer & Chief Information Security Officer

    • Tenure: 1.8yrs
  • Nobuhiro Abe

    Managing Corporate Officer & Government Affairs Head

    • Tenure: 0.0yrs
  • Hidenao Tsuchiya

    Corporate Officer & Global Group Compliance Officer

    • Tenure: 0.6yrs
  • Donna Miller

    Head of HQ Legal and Global General Counsel

    • Tenure: 3.3yrs
  • Mark Miller

    Global Chief Communications Officer

    • Tenure: 0.3yrs

Board Members

  • Sumitaka Fujita (77yo)

    Outside Director

    • Tenure: 7.3yrs
  • Nobuyuki Koga (69yo)

    Director

    • Tenure: 0.2yrs
  • Takayuki Katayama (74yo)

    Outside Director

    • Tenure: 3.2yrs
  • Susumu Kaminaga (73yo)

    Outside Director

    • Tenure: 3.2yrs
  • Michijiro Kikawa (72yo)

    Outside Director

    • Tenure: 3.2yrs
  • Masashi Shimizu (62yo)

    Director

    • Tenure: 0.2yrs
  • Katsuya Natori (60yo)

    Outside Director

    • Tenure: 0.2yrs
  • Hiro Sasa (64yo)

    Representative Director

    • Tenure: 7.3yrs
    • Compensation: JP¥114.98m
  • Yasuo Takeuchi (62yo)

    President

    • Tenure: 0.3yrs
  • Stefan Kaufmann (51yo)

    Chief Administrative Officer

    • Tenure: 0.2yrs

Company Information

Olympus Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Olympus Corporation
  • Ticker: OCPN.Y
  • Exchange: OTCPK
  • Founded: 1919
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: JP¥1.673t
  • Listing Market Cap: JP¥15.847b
  • Shares outstanding: 1.37b
  • Website: https://www.olympus-global.com

Number of Employees


Location

  • Olympus Corporation
  • Shinjuku Monolith
  • 3-1 Nishi-Shinjuku 2-chome
  • Tokyo
  • 163-0914
  • Japan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OCPN.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJan 1992
7733TSE (The Tokyo Stock Exchange)YesCommon StockJPJPYJan 1992
OLY1DB (Deutsche Boerse AG)YesCommon StockDEEURJan 1992
OCPN.YOTCPK (Pink Sheets LLC)SPONSORED ADRUSUSDSep 1995

Biography

Olympus Corporation manufactures and sells precision machineries and instruments worldwide. The company operates through four segments: Medical Business, Scientific Solutions Business, Imaging Business, an ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/24 00:01
End of Day Share Price2019/08/23 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.